StreetAccount Summary: Stocks reaching new 52-week highs/lows (30 total)
StreetAccount Sector Summary - Healthcare Post-Market
StreetAccount Sector Summary - Healthcare Pre-Market
Adlai Nortye initiated buy at HC Wainwright
Adlai Nortye reports H1 net income ($27.7M) vs year-ago ($78.6M)
Adlai Nortye to present preliminary data of AN0025 in combination with definitive chemoradiotherapy in unresectable locally advanced or locally recurrent esophageal cancer at ASCO
Adlai Nortye announces first patient dosed in randomized Phase II clinical trial of palupiprant (AN0025) for the treatment of locally advanced rectal cancer with radiation therapy
Powered by FactSet Research Systems Inc.